Press

Goodness Growth Holdings Subsidiary Resurgent Biosciences Announces Planned Expansion into Psychedelics Research and IP Development

Jun 9 • 2 min read

Quick Take: Goodness Growth Holdings has announced that their subsidiary Resurgent Biosciences plans to expand its intellectual property development and clinical research efforts into psychedelic medicine. Goodness Growth Holdings, Inc. (CSE: GDNS), a physician-led, science-focused cannabis company and IP incubator, today announced that its subsidiary, Resurgent Biosciences (“Resurgent”), plans to expand its intellectual property development…

American Journal of Psychiatry Publishes International Ketamine and Esketamine Treatment Guidance Led by Braxia Scientific CEO Dr. Roger Mcintyre

Jun 9 • 3 min read

Quick Take: The American Journal of Psychiatry has published international ketamine and esketamine treatment guidelines. These guidelines were developed and led by Braxia’s CEO Dr. Roger McIntyre, M.D. along with other medical experts across the world. Braxia Scientific Corp. (CSE: BRAX), a medical research company with clinics providing novel ketamine treatments for persons with depression…

MindMed Announces Chief Executive Officer Transition

Jun 9 • 5 min read

Quick Take: MindMed CEO and co-founder J.R. Rahn is stepping down as chief executive officer. Chief development officer Robert Barrow will assume the position of CEO with immediate effect. Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Company’s co-founder…

Leading Psychedelic Wellness Company Delic Signs Definitive Agreement to Acquire Ketamine Infusion Centers Llc.

Jun 8 • 5 min read

Quick Take: Delic Holdings has entered an agreement to acquire Ketamine Infusion Centers, which owns and operates two ketamine clinics in Phoenix, Arizona. Delic Holdings Inc. (CSE: DELC), the leading psychedelic wellness platform has signed a definitive agreement to acquire Ketamine Infusion Centers LLC. KIC is a limited liability corporation formed under the laws of Arizona,…

Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic Medicine

Jun 7 • 3 min read

Quick Take: Mindset Pharma’s MSP-1014, a differentiated psychedelic compound, showed greater safety and efficacy in in vitro and in vivo preclinical models Mindset Pharma Inc. (CSE: MSET), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435